1. Introduction {#sec1}
===============

Globalization and climate changes continue to reshape the geographical distribution of humans, animals, vectors, and microbes, and allow their mixing to occur at an unprecedentedly high frequency ([@bib8]). These have led to interspecies transmission of numerous emerging pathogens in the past few decades, such as avian influenza viruses, severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses, Ebola virus, and other viruses causing hemorrhagic fever ([@bib7]; [@bib33]; [@bib34]; [@bib41]; [@bib42]). The latest emerging viral epidemic that was declared as an international health emergency is the one caused by Zika virus (ZIKV) ([@bib36]). ZIKV is a human-pathogenic flavivirus that has been neglected until recently, when it was found that ZIKV infection may be associated with severe clinical complications, including congenital microcephaly and other anomalies, neurological complications such as Guillain-Barre syndrome and meningoencephalitis, ophthalmological defects, auditory impairment, and rarely, multi-organ involvement and death ([@bib6]; [@bib36]).

ZIKV infection, similar to other emerging viral infections, may have non-specific clinical manifestations during the early phase of the disease ([@bib6]; [@bib21]). For example, ZIKV infection may manifest as an acute febrile illness with rash and systemic upset which may be indistinguishable from dengue fever and other viral hemorrhagic fever syndromes ([@bib6]; [@bib21]). Moreover, ZIKV may co-circulate with other viruses in the same geographical regions and co-infect the same patient ([@bib36]). As in the case of most other emerging viral infections, there are currently limited treatment options proven to be effective and safe for ZIKV infection. Thus, broad-spectrum agents that can be used as empirical treatment for patients with an acute undifferentiated febrile illness before the diagnosis is confirmed by laboratory tests are urgently needed.

An important group of drugs that have broad-spectrum antiviral activities are agents that target host pathways or enzymes that are involved in the replication cycles of different viruses ([@bib48]). For example, host cellular kinases have been increasingly implicated in the pathogenesis of viral infections as they may be exploited by viruses to facilitate their own replication ([@bib16]; [@bib32]; [@bib39]; [@bib44]). For flaviviruses, the phosphatidylinositol 3 kinase/protein kinase B (PI3K/Akt) pathway has been shown to enhance viral replication through counteracting virus-induced cellular apoptosis ([@bib29]; [@bib43]). AR-12 (OSU-03012), an FDA-approved investigational new drug (IND) compound, is a celecoxib derivative kinase inhibitor that does not inhibit cyclooxygenase activity, but instead downregulates the PI3K/Akt pathway which are involved in multiple cell signaling pathways ([@bib12]; [@bib35]). AR-12 has been evaluated in phase I clinical trials as an anticancer agent in adult patients with advanced or recurrent solid tumors or lymphoma (Clinical Trials registration no. NCT00978523).

In addition to its anti-cancer effects, AR-12 has exhibited *in vitro* and/or *in vivo* antimicrobial activities against a wide range of pathogens. These microbes included intracellular bacteria (*Salmonella enterica* and *Francisella tularensis*), fungi (*Candida albicans,* non-albicans *Candida* sp., *Cryptococcus neoformans*, *Fusarium* sp., mucorales, *Blastomyces dermatitidis*, *Histoplasma capsulatum*, and *Coccidioides immitis*), parasite (*Leishmania donovani*), and viruses (Lassa, Marburg, and Ebola viruses) ([@bib14]; [@bib15]; [@bib19]; [@bib28]; [@bib35]). Importantly, the European Commission has designated AR-12 as an orphan drug that could be used clinically in combination with other anti-infective agents for treatment of cryptococcosis (with fluconazole) and tularemia (with gentamicin) ([@bib1]). These clinical experiences make AR-12 a clinically readily available drug for emerging infectious diseases lacking effective treatment options. Recently, AR-12 was reported to have *in vitro* and *in vivo* antiviral activity against dengue virus (DENV), another flavivirus that is closely related to the emerging ZIKV ([@bib12]; [@bib23]). We therefore hypothesized that this broad-spectrum host-targeting antiviral drug may also exhibit inhibitory activity against ZIKV. In this study, we evaluated the *in vitro* and *in vivo* antiviral activity of AR-12 against ZIKV and investigated the mechanism of AR-12\'s anti-ZIKV activity.

2. Materials and methods {#sec2}
========================

2.1. Ethics and biosafety {#sec2.1}
-------------------------

The animal experiments were approved by the Committee on the Use of Live Animals in Teaching and Research of The University of Hong Kong and performed according to established safety protocols in the biosafety level-2 laboratory at Department of Microbiology, The University of Hong Kong.

2.2. Virus strains, cell lines, and drug compounds {#sec2.2}
--------------------------------------------------

ZIKV-PR (Puerto Rico strain PRVABC59) was isolated from a patient in the recent South American epidemic (kindly provided by Brandy Russell and Barbara Johnson, Centers for Disease Control and Prevention, USA). ZIKV-GD was isolated from a Chinese patient who returned to Guangdong after being infected by ZIKV while traveling to the Americas (kindly provided by George F. Gao, Chinese Academy of Sciences, China). ZIKV-U (976 Uganda strain) was isolated from a nonhuman primate in Uganda in 1947 (kindly provided by Tatjana Avšič Županc, University of Ljubljana, Slovenia, the European Virus Archive). The virus strains were cultured and titrated as we previously described ([@bib10]; [@bib46]). The U251 and SF268 cell lines were obtained from American Type Culture Collection, and the Huh-7 cell line was obtained from JCRB cell bank of Okayama University, Japan ([@bib10]). AR-12 and the Akt inhibitor (Akt Inhibitor VIII) were purchased from InvivoGen (SanDiego, CA, USA) and Millipore (Burlington, MA, USA), respectively. ON-TARGETplus human Akt siRNA and ON-TARGETplus non-targeting siRNA were purchased from Dharmacon (Lafayette, CO, USA).

2.3. CellTiter-Glo^®^ luminescent cell viability assay {#sec2.3}
------------------------------------------------------

The 50% effective cytotoxic concentration (CC~50~) of AR-12 in Huh-7, U251, and SF268 cells and the cell protection effects of AR-12 against ZIKV infection in these cell lines were determined by the CellTiter-Glo^®^ luminescent cell viability assay (PromegaCorporation, Madison, WI, USA) according to the manufacturer\'s instructions and as previously described ([@bib35]). For determination of CC~50~ of AR-12 treatment without ZIKV infection, the cells were treated with different concentrations of AR-12 (0--20 μM) for 48 h. For cell protection effects, the cells were infected by ZIKV-PR at 0.50 multiplicity of infection (MOI) for 1 h and then treated with dimethyl sulfoxide (DMSO) (ie: 0 μM AR-12) or up to 3 μM AR-12 for 48 h. After 48 h, the reconstituted CellTiter-Glo^®^ reagent was added to the cells according to the manufacturer\'s instructions. The luminescent signal was detected by the Victor X3 2030 Multilabel Reader (PerkinElmer) according to the manufacturer\'s instructions.

2.4. Antiviral evaluation of AR-12 in cell culture {#sec2.4}
--------------------------------------------------

The antiviral activity of AR-12 against ZIKV was evaluated in cell culture as previously described ([@bib5]; [@bib46]). Briefly, ZIKV-infected Huh-7, U251, and SF268 cells (MOI = 0.05) were treated with different concentrations of AR-12 or DMSO. The cell culture supernatants were then collected at 24 h post-inoculation (hpi), followed by total nucleic acid extraction and quantitative reverse transcription-PCR (qRT-PCR) as previously described ([@bib10]; [@bib9]). Additionally, U251 cells were inoculated with high MOI of ZIKV (MOI = 1) for 1 h. After the virus inoculum was removed, the cells were washed and cultured in fresh medium containing different concentrations of AR-12 or DMSO. At 24 hpi, the supernatants were collected and subsequently applied for virus titration using both qRT-PCR and plaque assay. The half maximal inhibitory concentration (IC~50~) was calculated using Sigma plot in an Excel add-in ED50V10 as we previously described ([@bib4]; [@bib5]; [@bib9]).

2.5. Flow cytometry {#sec2.5}
-------------------

To more thoroughly compare the differences between the percentage of cells infected by ZIKV in AR-12-treated versus untreated samples, flow cytometry and immunostaining was performed as we previously described with slight modifications ([@bib18]; [@bib17]). Briefly, U251 cells were infected with ZIKV-PR at 0.50 MOI or were mock-infected for 1 h at 37 °C. After 1 h, the inoculum was removed and the cells were washed with phosphate-buffered saline (PBS). Dulbecco\'s Modified Eagle Medium (DMEM) with 3 μM AR-12 or 1% DMSO (Sigma-Aldrich, St.Louis, MO, USA) was then added to the cells. At 24 hpi, the cells were detached by using 10 mM ethylenediaminetetraacetic acid (EDTA)/PBS and fixed in 4% paraformaldehyde. For immunostaining, the cells were first permeabilized with 0.1% Triton X-100 in PBS and then blocked with 2% fetal bovine serum (FBS) in PBS. ZIKV was detected with a mouse anti-ZIKV-NS1 primary antibody (Abcam, Cambridge, United Kingdom) or the mouse anti-pan-flavivirus primary antibody 4G2 (Millipore) and Alexa Fluor 488 goat anti-mouse immunoglobulin (IgG) (Invitrogen, Carlsbad, CA, USA) as the secondary antibody. Flow cytometry was performed using a BD FACSCanto II flow cytometer (BD Biosciences, San Jose, CA, USA) and the data were analyzed using FlowJo vX (Tree Star).

2.6. Western blot {#sec2.6}
-----------------

Huh-7 cells were lysed with radioimmunoprecipitation assay (RIPA) lysis buffer (Thermo Fisher Scientific, Waltham, MA, USA) with protease inhibitors cocktail (Sigma-Aldrich). Western blotting was performed as we previously described with slight modifications ([@bib3]). Briefly, proteins were separated with electrophoresis on 10% sodium dodecyl sulfate (SDS) gels and transferred onto polyvinylidene difluoride (PVDF) membranes. The PVDF membranes were subsequently blocked with 3% bovine serum albumin (BSA) for 1 h at room temperature and incubated with the primary antibodies at 4 °C overnight. On the next day, the membranes were washed thrice with 0.1% PBS with Tween 20 buffer and incubated with peroxidase-conjugated secondary antibodies for 2 h at room temperature. The protein bands on the membranes were visualized by using horseradish peroxidase (HRP) substrate (Bio-Rad, Hercules, CA, USA). The antibodies used for Western blotting in this study were as follows: anti-Akt 1 antibody \[M1843\] (ab108202, Abcam), anti-pan-Akt (phosphor T308) antibody (ab38449, Abcam), goat anti-rabbit IgG (H + L) secondary antibody (HRP 65--6120, Thermo Fisher), and goat anti-mouse IgG (H + L) secondary antibody (HRP 62--6520, Thermo Fisher).

2.7. Akt inhibitor and small interfering RNA (siRNA) knockdown {#sec2.7}
--------------------------------------------------------------

In the Akt inhibitor assay, Huh-7 cells were inoculated with ZIKV for 1 h at 37 °C. At 1 hpi, the inoculum was removed and the cells were washed with PBS. DMEM containing 15 μM Akt inhibitor or 1% DMSO was added to the ZIKV-infected cells. At 24 hpi, the supernatants were harvested in RLT buffer and RNA was extracted with the EZ1 RNA tissue mini kit (Qiagen, Hilden, Germany). The viral load was then quantified with qRT-PCR as we previously described ([@bib10]; [@bib9]). In the siRNA knockdown assay, transfection of siRNA on Huh-7 cells was performed using Lipofectamine^®^ RNAiMAX (Thermo Fisher Scientific) as we previously described with slight modifications ([@bib3]). Briefly, 70 nM Akt siRNA or scramble siRNA was mixed with RNAiMAX and Opti-MEM, which was then used to transfect Huh-7 cells. At 24 h post-transfection, the siRNA-transfected cells were inoculated with ZIKV for 1 h at 37 °C. At 1 hpi, the inoculum was removed and the cells were washed with PBS. DMEM was then added to the cells. At 24 hpi, the supernatants were harvested in RLT buffer and RNA was extracted with the EZ1 RNA tissue mini kit (Qiagen). The viral RNA load was then quantified with qRT-PCR as we previously described ([@bib10]; [@bib9]).

2.8. A129 mouse model for ZIKV infection and *in vivo* evaluation of AR-12 treatment {#sec2.8}
------------------------------------------------------------------------------------

The type I interferon receptor-deficient lethal A129 mouse model for ZIKV infection was performed as previously described with slight modifications ([@bib20]; [@bib22]). Briefly, 4-6-week-old A129 mice (Mutant Mouse Resource Research Centers, USA) were randomly divided into different groups to receive AR-12 treatment or sham treatment (n = 12-24/group). Additional groups of uninfected mice receiving intraperitoneal or oral AR-12 treatment were also included as controls ([Table S1](#appsec1){ref-type="sec"}). The mice were inoculated subcutaneously with 8 × 10^6^ plaque-forming units (PFU) (in 80 μl PBS) of ZIKV-PR under anesthesia at 0 days post-infection (dpi). Each mouse then received 1 dose of intraperitoneally administered AR-12 (25 mg/kg intraperitoneally or 200 mg/kg orally by oral gavage suspended in PBS with 0.5% methylcellulose-0.1% Tween 80) or sham treatment (PBS) at 1 hpi or 48 hpi as previously described ([Table S1](#appsec1){ref-type="sec"}) ([@bib12]; [@bib30]). The mice were monitored three times per day for body weight change and clinical signs of disease as previously described ([@bib20]). Six (12 for sham treatment control group) mice in each group were euthanized when there was ≥20% weight loss or ≥10% weight loss with ≥1 clinical sign or at 6 dpi (the expected day of death of all untreated control mice). Their blood and organ tissues were collected for viral load studies as previously described ([@bib11]; [@bib46]). The survival of the other mice was monitored until 14 dpi.

2.9. Statistical analysis {#sec2.9}
-------------------------

All data were analyzed with GraphPad Prism software (GraphPad Software, Inc) as we previously described ([@bib11]). Kaplan-Meier survival curves were analyzed by the log rank test, and weight losses were compared using two-way ANOVA. Student\'s *t*-test was used to determine significant differences in viral loads, and Tukey-Kramer post hoc test was used to discern differences among the groups. *P* \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. AR-12 inhibited the replication of ZIKV strains belonging to both the Asian/American and African lineages {#sec3.1}
--------------------------------------------------------------------------------------------------------------

Both the Asian/American and African lineages of ZIKV are considered to be pathogenic and medically important ([@bib36]; [@bib40]; [@bib47]). We therefore evaluated the antiviral activity of AR-12 against ZIKV strains belonging to both lineages. In the viral load reduction assay, AR-12 inhibited the replication of all 3 ZIKV strains used in the study, including ZIKV-PR (Asian/American), ZIKV-GD (Asian/American), and ZIKV-U (African), in Huh-7 cells in a dose-dependent manner ([Fig. 1](#fig1){ref-type="fig"} ). The reduction in viral RNA load of all 3 ZIKV strains was ∼1.0--1.5 logs in culture supernatant and cell lysate of AR-12-treated samples. These findings demonstrated that AR-12 could inhibit both the Asian/American and African lineages of ZIKV.Fig. 1**AR-12 inhibits the replication of ZIKV strains belonging to both the Asian/American and African lineages in Huh-7 cells.** Dose-dependent reduction of ZIKV RNA load was observed at 24 h after ZIKV-PR, ZIKV-GD, or ZIKV-U inoculation (0.05 MOI) in Huh-7 cells with 0--3 μM AR-12. All experiments were performed in triplicates in three independent experiments for confirmation. \* denotes *P* \< 0.05, \*\* denotes *P* \< 0.01, and \*\*\* denotes *P* \< 0.001 (compared with the DMSO control group by Student\'s *t*-test). Data are presented as mean values ± standard deviations (error bars). Abbreviations: ZIKV, Zika virus.Fig. 1

3.2. AR-12 effectively inhibited multi-cycle replication of ZIKV *in vitro* {#sec3.2}
---------------------------------------------------------------------------

To further characterize the inhibition of ZIKV by AR-12, we prolonged the incubation of Huh-7 cells infected with ZIKV-PR and either AR-12 or DMSO for up to 72 h to study their differential viral kinetics. As shown in [Fig. 2](#fig2){ref-type="fig"} , the ZIKV-PR RNA loads in both the culture supernatant and cell lysate of the AR-12-treated samples were consistently ∼1.0--1.5 logs lower than those of the DMSO-treated controls at multiple time points (24, 48, and 72 hpi). The CC~50~, IC~50~, and selectivity index of AR-12 in Huh-7 cells were 7.01 μM, 0.82--0.88 μM (culture supernatant and cell lysate), and 7.97--8.55, respectively.Fig. 2**AR-12 effectively inhibits multi-cycle replication of ZIKV *in vitro***. Differential viral kinetics of ZIKV in Huh-7 cells with or without AR-12 from 0 to 72 hpi. The ZIKV-PR RNA load in both the culture supernatant (top) and cell lysate (bottom) of the AR-12-treated (3 μM) samples were consistently ∼1.0--1.5 logs lower than those of the DMSO-treated controls at different time points (24, 48, and 72 hpi). All experiments were performed in triplicates in three independent experiments for confirmation. \*\*\* denotes *P* \< 0.001 (compared with the DMSO control group at the corresponding time point by Student\'s *t*-test). Data are presented as mean values ± standard deviations (error bars). Abbreviations: DMSO, dimethyl sulfoxide; hpi, hours post-inoculation; ZIKV, Zika virus.Fig. 2

3.3. AR-12 provided cell protection effects against ZIKV infection {#sec3.3}
------------------------------------------------------------------

In addition to inhibition of viral replication, it was important to determine if cell protection effects against ZIKV infection were present in AR-12-treated cells. In the cell viability assay, a dose-dependent increase in the percentage of viable cells was observed in AR-12-treated Huh-7 cells ([Fig. 3](#fig3){ref-type="fig"} ). The mean cell viability increased from 55.6% in untreated Huh-7 cells to approximately 100% in cells treated with 3 μM AR-12, suggesting that AR-12 provided cell protection effects against ZIKV infection.Fig. 3**AR-12 provided cell protection effects against ZIKV infection.** Cell viability assay showing dose-dependent increase in the percentage of viable cells in AR-12-treated Huh-7 cells. All experiments were performed in triplicates in three independent experiments for confirmation. \* denotes *P* \< 0.05 and \*\*\* denotes *P* \< 0.001 (compared with the DMSO control group by Student\'s *t*-test). Data are presented as mean values ± standard deviations (error bars).Fig. 3

3.4. AR-12 inhibited ZIKV replication in multiple cell types {#sec3.4}
------------------------------------------------------------

The major clinical manifestations of ZIKV infection, such as congenital microcephaly and meningoencephalitis, mainly involve neuronal cells. To confirm the observation in the viral load reduction assay using Huh-7 cells, we further evaluated the antiviral activity of AR-12 against the epidemic ZIKV-PR strain in two neuronal (glioblastoma) cell lines, namely, U251 and SF268. As shown in [Fig. 4](#fig4){ref-type="fig"} , the ZIKV-PR RNA load was significantly reduced by AR-12 in both U251 (*P* \< 0.01) and SF268 cells (*P* \< 0.001). The CC~50~, IC~50~, and selectivity index of AR-12 in U251 cells were 6.99 μM, 0.84 μM, and 8.32, respectively, and those in SF268 cells were 11.00 μM, 1.18 μM, and 9.32, respectively. The antiviral activity of AR-12 against ZIKV was confirmed even at high MOI by both qRT-PCR and plaque assays ([Fig. 5](#fig5){ref-type="fig"} ). We next further evaluated the impact of AR-12 on the antigen expression of ZIKV-PR in neuronal cells with flow cytometry ([Fig. 6](#fig6){ref-type="fig"} ). Remarkably, our result demonstrated that AR-12 significantly inhibited the expression of both the envelope protein ([Fig. 6](#fig6){ref-type="fig"}A) and non-structural protein 1 ([Fig. 6](#fig6){ref-type="fig"}B) of ZIKV-PR in the infected cells. The inhibition was evidenced by the reduction in the percentage of positive cells ([Fig. 6](#fig6){ref-type="fig"}C) as well as the reduction in the mean fluorescent intensity ([Fig. 6](#fig6){ref-type="fig"}D).Fig. 4**AR-12 inhibits ZIKV replication in neuronal cells.** Significant reduction of ZIKV-PR (MOI = 0.05) RNA load was observed at 24 hpi in U251 and SF268 cells with 3 μM AR-12 compared with DMSO (0 μM AR-12) control. All experiments were performed in triplicates in three independent experiments for confirmation. \*\* denotes *P* \< 0.01 and \*\*\* denotes *P* \< 0.001 (compared with the DMSO control group by Student\'s *t*-test). Data are presented as mean values ± standard deviations (error bars). Abbreviations: DMSO, dimethyl sulfoxide; hpi, hours post-inoculation; ZIKV, Zika virus.Fig. 4Fig. 5**AR-12 inhibits ZIKV replication at high MOI.** Dose-dependent reduction of ZIKV-PR (MOI = 1) RNA load in qRT-PCR (top) and virus titer in plaque assay (bottom) in U251 cells with different concentrations of AR-12 compared with DMSO (0 μM AR-12) control. All experiments were performed in triplicates in three independent experiments for confirmation. \* denotes *P* \< 0.05 and \*\* denotes *P* \< 0.01 (compared to the DMSO control group by Student\'s *t*-test). Data are presented as mean values ± standard deviations (error bars). Abbreviations: ZIKV, Zika virus.Fig. 5Fig. 6**AR-12 inhibits the antigen expression of ZIKV-PR in U251 cells.** U251 cells were infected with ZIKV-PR at 0.5 MOI or were mock-infected for 1 h at 37 °C. The infected cells were subsequently treated with 3 μM AR-12 or DMSO for 24 h. At 24 hpi, the cells were harvested and immunolabeled for flow cytometry analysis. The expression level of ZIKV envelope protein (A) and non-structural 1 protein (B) were labeled with mouse anti-4G2 and mouse anti-NS1, respectively. The percentage of 4G2 or NS1 positive cells (C) and the mean fluorescent intensity (D) were quantified. All experiments were performed in triplicates in three independent experiments for confirmation. \* denotes *P* \< 0.05 and \*\* denotes *P* \< 0.01 (compared with the DMSO control group by Student\'s *t*-test). Data are presented as mean values ± standard deviations (error bars). Abbreviations: DMSO, dimethyl sulfoxide; hpi, hours post-inoculation; MFI, mean fluorescence intensity; NS1, non-structural protein 1; ZIKV, Zika virus.Fig. 6

3.5. AR-12 treatment improved clinical and virological outcome of ZIKV-infected A129 mice {#sec3.5}
-----------------------------------------------------------------------------------------

To assess the *in vivo* anti-ZIKV activity of AR-12, we infected type I interferon-receptor-deficient A129 mice with ZIKV-PR and treated them with either AR-12 or sham treatment. The ZIKV-infected mice treated with AR-12 early after infection (1 hpi) had less mean body weight loss (\<10%) ([Fig. 7](#fig7){ref-type="fig"} A) and significantly higher survival rate (83.3% vs 0%, *P* \< 0.001) ([Fig. 7](#fig7){ref-type="fig"}B) than the untreated ZIKV-infected controls. Moreover, the mean ZIKV RNA loads in the blood and necropsied tissues of these AR-12-treated mice at necropsy were generally 0.8--1.5 logs lower than those of the untreated mice ([Fig. 7](#fig7){ref-type="fig"}C). We also evaluated regimens of delayed administration of AR-12 either intraperitoneally or by oral gavage to ZIKV-infected mice at 48 hpi to more closely mimic clinical situations in which viremic patients do not receive treatment immediately after infection. The improved clinical and virological parameters were more obvious in the mice treated with the oral regimen, which consisted of a much higher dose (200 mg/kg) of AR-12 than the intraperitoneal regimen (25 mg/kg) ([Fig. 7](#fig7){ref-type="fig"}). These findings illustrated that AR-12 not only inhibited ZIKV *in vitro*, but also *in vivo*, especially if given early or at a high dose.Fig. 7**AR-12 treatment improves clinical and virological outcome of ZIKV-infected A129 mice.** (A) Body weight trend, (B) survival rate, and (C) blood and tissue ZIKV RNA loads in the AR-12-treated ZIKV-infected and untreated A129 mice. The mice were treated with 1 dose of 25 mg/kg AR-12 intraperitoneally at 1 hpi, 25 mg/kg AR-12 intraperitoneally at 48 hpi, 200 mg/kg orally AR-12 at 48 hpi, or sham treatment (PBS) ([Table S1](#appsec1){ref-type="sec"}). Six (12 for sham treatment controls) mice in each group were euthanized when there was ≥20% weight loss or ≥10% weight loss with ≥1 clinical sign or at 6 dpi for blood and organ tissue collection. ZIKV RNA loads in the blood (copies/ml) and tissues (copies/10^6^ β-actin) (C) of the mice were determined by qRT-PCR. The body weight and the survival rate of the other mice were monitored from 0 to 14 dpi or until death/euthanasia. The results were combined from four independent experiments. The body weight trends represented those of the survived mice. Statistical significance in (C) represented the difference between the individual treatment groups with the sham treatment control group. \* denotes *P*-values of \<0.05, \*\* denotes *P-*values of \<0.01, and \*\*\* denotes *P*-values of \<0.001. Data are presented as mean values ± standard deviations (error bars). Abbreviations: ip, intraperitoneal; PBS, phosphate-buffered saline; po, per os; ZIKV, Zika virus.Fig. 7

3.6. AR-12 inhibited ZIKV replication via down-regulation of Akt {#sec3.6}
----------------------------------------------------------------

Downregulation of 78 kDa glucose-regulated protein (GRP-78) and/or Akt has been previously proposed to be the anti-DENV mechanism of AR-12 ([@bib12]). Surprisingly, in contrast to this previous report, we did not find AR-12 to be downregulating GRP-78 ([Fig. 8](#fig8){ref-type="fig"} A). Instead, we found that AR-12 substantially downregulated the phosphorylation of the Akt protein ([Fig. 8](#fig8){ref-type="fig"}B). In this regard, our data suggested that AR-12 potentially inhibited ZIKV replication by negatively regulating the Akt signaling pathway. To further investigate if the Akt signaling pathway modulated ZIKV replication, we treated ZIKV-infected Huh-7 cells with an Akt inhibitor, Akt inhibitor VIII, which has been previously shown to inhibit Akt activation ([@bib31]). Interestingly, our result demonstrated that ZIKV replication was significantly (*P* \< 0.05) inhibited in the presence of Akt inhibitor VIII ([Fig. 8](#fig8){ref-type="fig"}C). The involvement of the Akt signaling pathway in ZIKV replication was further validated with siRNA knockdown ([Fig. 8](#fig8){ref-type="fig"}D). Akt knockdown resulted in a significant (*P* \< 0.01) decrease in ZIKV replication, which was in agreement with the result of the Akt inhibitor VIII experiment ([Fig. 8](#fig8){ref-type="fig"}E). Taken together, these findings suggested that AR-12 inhibits ZIKV replication through downregulation of the Akt signaling pathway.Fig. 8**AR-12 inhibits ZIKV replication via down-regulation of Akt.** AR-12 did not downregulate the expression of GRP-78 (A), but reduced Akt phosphorylation (B). Addition of Akt Inhibitor VIII (C) significantly reduced ZIKV RNA load. Similarly, Akt siRNA used in this study downregulated the expression levels of Akt and pAkt (D) and significantly reduced ZIKV RNA load (E). All experiments were performed in triplicates in three independent experiments for confirmation. \* denotes *P* \< 0.05 and \*\* denotes *P* \< 0.01 (compared with the DMSO or scramble siRNA control groups by Student\'s *t*-test). Data in [Fig. 8](#fig8){ref-type="fig"}C and E are presented as mean values ± standard deviations (error bars). Abbreviations: Akt, protein kinase B; DMSO, dimethyl sulfoxide; GRP-78, 78 kDA glucose-regulated protein; NS1, non-structural protein 1; pAkt, phosphorylated protein kinase B; ZIKV, Zika virus.Fig. 8

4. Discussion {#sec4}
=============

Drug compounds that target common host pathways involved in the replication cycles of different viruses have the potential advantage of being broad-spectrum antivirals ([@bib48]). This is especially important for arboviruses such as ZIKV, DENV, and Chikungunya virus, which co-circulate in the same geographical regions and/or have similar clinical features. We and others have previously identified a number of clinically approved drugs, such as novobiocin, lopinavir-ritonavir, ribavirin, and sofosbuvir, to have anti-ZIKV activity *in vitro* and/or *in vivo* ([@bib2]; [@bib27]; [@bib46]). These repurposed drugs directly target the virus by inhibition of key viral enzymes, such as the viral protease and polymerase, and may not have antiviral activity against other co-circulating arboviruses with structurally different viral enzymes.

Host-targeting treatment options for ZIKV remain scarce. We have previously shown the *in vitro* and *in vivo* anti-ZIKV activity of recombinant interferons, but their side effect profiles may limit their clinical use, especially in pregnant women ([@bib5]; [@bib11]). A recent study reported the *in vitro* anti-ZIKV activity of a protein kinase A inhibitor (PKI 14--22) in endothelial cells and astrocytes. Another recent study reported that the activation of adenosine monophosphate-activated protein kinase by a small molecule activator (PF-06409577) inhibited ZIKV replication through modulation of host cell lipid metabolism ([@bib26]). These findings supported our hypothesis that drugs which target host signaling pathways may be useful for treating ZIKV infection ([@bib13]). During the preparation of this work, AR-12 and a few other kinase inhibitors were recently identified to exhibit *in vitro* anti-ZIKV activity in human osteosarcoma (U2OS) cells in a drug screening programme ([@bib38]). However, no further validation of this preliminary finding in other clinically relevant cell lines or suitable animal model was reported, and the anti-ZIKV mechanism of AR-12 was not investigated. In this study, we demonstrated the anti-ZIKV activity of AR-12 *in vitro* and *in vivo*, and provided novel insights into the drug\'s anti-ZIKV mechanism.

We first showed that AR-12 inhibited the replication of ZIKV belonging to both the American/Asian and African lineages. This was important as both lineages of ZIKV are considered to be pathogenic to human. Moreover, treatment with AR-12 provided cell protection effects against ZIKV-induced damage. The anti-ZIKV activity of AR-12 was then validated in multiple cell types, including neuronal cells which are clinically relevant for the neurotropic ZIKV. Importantly, type I interferon receptor-deficient A129 mice treated with AR-12 (either early or delayed regimen) had significantly higher survival rates and lower viral loads than untreated mice, suggesting that the anti-ZIKV effect of AR-12 was not only present *in vitro,* but also in a lethal animal model. We further demonstrated that AR-12 inhibited the phosphorylation of Akt, which is a downstream component of the PI3K/Akt signaling pathway that promotes flavivirus replication by counteracting virus-induced cellular apoptosis.

The ZIKV RNA load reduction (∼1.0--1.5 logs) observed in our cell culture systems and animal model with AR-12 treatment is comparable with previous findings on AR-12\'s antiviral effects against other RNA viruses. For example, the CC~50~, IC~50~, and selectivity index values of AR-12 against other hemorrhagic fever viruses were comparable with our findings for ZIKV ([@bib35]). For flaviviruses, there was about 1 log reduction of DENV RNA load with 2--4 μM AR-12 and the IC~50~ values of AR-12 against DENV serotypes 1--4 were between 0.60 μM and 0.80 μM in Vero cells ([@bib23]). The CC~50~ of AR-12 was higher in Vero cells (65.90 μM) than in our Huh-7 and neuronal cells, suggesting that the selectivity index of AR-12 against flaviviruses may be even higher in other cell types (up to \>100) ([@bib23]). In DENV-infected suckling mice treated with AR-12 intracranially and intraperitoneally, there was about 0.5--0.7 log reduction in infectious virus particles (plaque forming units) in their brain tissues ([@bib12]). In comparison, virus-targeting drugs often achieve a higher degree of viral load reduction (\>2 logs) *in vitro* and *in vivo*. For example, the ZIKV NS2B-NS3 protease inhibitor novobiocin reduces ZIKV RNA load by ≥ 2 logs both *in vitro* (Vero and Huh-7 cells) and in the blood and tissues of ZIKV-infected mice ([@bib46]). Our recently described antiviral peptide (Z2 peptide) targeting the stem region of the ZIKV envelope protein to inhibit virus entry into host cells significantly reduced viral RNA load in ZIKV-infected interferon receptor-deficient mice and inhibited vertical transmission of ZIKV in pregnant C57BL/6 mice ([@bib45]). These findings are not unexpected as our mice only received one dose of AR-12 treatment post-infection and because AR-12\'s antiviral mechanism via downregulation of the PI3K/Akt signaling pathway is not as direct as those of virus-targeting drugs.

AR-12 has the advantages of being broad-spectrum and orally available, and may be clinically useful as an empirical therapy before laboratory diagnosis is established in patients living in or returning from endemic areas of arboviral and hemorrhagic fever viral diseases who develop an acute febrile illness. The effect of AR-12 as part of combination treatment regimens consisting of both virus-targeting and host-targeting drugs should be evaluated in future studies, as this treatment strategy may be associated with improved clinical outcomes for ZIKV and other RNA viral infections ([@bib25]; [@bib37]; [@bib48]). Further optimization of the delivery of AR-12, such as encapsulation of the drug into biodegradable polymeric nanoparticles to reduce cytotoxicity and increase drug concentration per cell may facilitate its use in these clinical settings ([@bib19]; [@bib24]).
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